Alembic Pharmaceuticals Ltd Share Price

Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg

NSE: APLLTD Small Cap ISIN: INE901L01018

As on 31 January 2025 at 13:59 IST

₹913.20

+ 2.10

(0.23%)

Sell Buy

About Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd stands as a prominent figure in the pharmaceutical industry. It boasts a rich history dating back to its founding in the year 1907. With over a century of experience, this Gujarat-based company has established itself as a key player in the healthcare sector. It specializes in the manufacture and marketing of branded and generic drugs, as well as active pharmaceutical ingredients (APIs). Headquartered in the city of Vadodara, Alembic’s product portfolio is diverse. The company’s products encompasses antibiotics, anti-infectives, analgesics, and anti-inflammatory drugs, showcasing its expertise in this area. Read More...

Over 1 Month

-13%

Over 6 Months

-22.39%

Over 1 Year

1.10%

Over 3 Years

20.40%

Alembic Pharmaceuticals Ltd Summary

Close ₹ 913.20

Open ₹ 915

High ₹ 927.95

Low ₹ 908.15

Volume 19,593

Net Turnover (in ₹ Cr) ₹ 7.62

52Wk High ₹ 1,303.90

52Wk Low ₹ 823.40

52Wk High / Low

823.40

1,303.90

Alembic Pharmaceuticals Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 17,908.87

EPS (TTM) 38.99

Book Value (BV) 255.98

Div. Yield 1.21 %

P/E (TTM) 23.06

Price/Book Value 3.56

Delivery % 41.41 %

Face Value 2

Key Ratios

PE Ratio 28.97

PB Ratio 3.93

EV to Sales 3.37

PEG Ratio 0.31

ROA 12.09

ROE 14.30

Debt-Equity 0.13

Net Profit Margin 11.35

Operating Profit Margin 17.53

Alembic Pharmaceuticals Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	6,256.93	5,655.36	5,356.25	5,480.42	4,610.69
Total Expenses	5,624.13	5,269.86	4,736.14	4,112.34	3,567.22
Profit Before Tax	631.83	354.59	625.39	1,368.08	999.82
Profit After Tax	615.82	341.99	520.94	1,114.76	800.64
Operating Profit after Depreciation	688.99	435.67	637.84	1,384.10	1,070.63

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	2,546.71	2,398.45	1,896.29	2,026.67	1,823.92
Total Non Current Assets	3,367.02	3,272.81	4,261.24	4,056.96	3,526.30
Total Current Assets	3,078.56	2,910.02	2,860.79	2,652.02	2,462.75
TOTAL ASSETS	6,445.58	6,182.83	7,122.03	6,708.98	5,989.05
Total Shareholder's Fund	4,818.20	4,370.47	5,237.54	5,066.97	3,219.41

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	803.20	723.95	552.35	1,463.39	449.13
Net Cash used in Investing Activities	-320.61	-447.60	-371.97	-839.74	-731.22
Net Cash used in Financing Activities	-437.86	-261.96	-217.35	-597.43	154.86

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	5,905.38	5,152.54	5,086.55	5,150.79	4,267.30
Total Expenses	5,201.15	4,806.61	4,428.54	3,813.05	3,090.51
Profit Before Tax	704.23	345.93	658.01	1,337.74	1,166.79
Profit After Tax	666.48	346.73	543.55	1,096.54	969.40
Operating Profit after Depreciation	758.70	394.93	675.03	1,350.72	1,201.98

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	2,535.66	2,377.45	1,869.54	2,012.07	1,268.11
Total Non Current Assets	3,409.99	3,350.20	4,329.57	4,148.87	3,727.40
Total Current Assets	2,988.55	2,780.22	2,744.47	2,494.60	2,151.37
TOTAL ASSETS	6,398.54	6,130.42	7,074.04	6,643.47	5,878.77
Total Shareholder's Fund	4,908.91	4,414.30	5,290.34	5,101.81	3,346.01

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	772.77	730.25	545.26	1,388.48	539.75
Net Cash used in Investing Activities	-329.02	-460.98	-368.72	-836.65	-821.91
Net Cash used in Financing Activities	-445.29	-261.16	-216.64	-533.76	166.13

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	1,647.98	1,561.73	1,516.98	1,630.57	1,594.93
Total Expenses	1,408.71	1,324.90	1,257.31	1,364.25	1,387.19
Profit Before Tax	180.42	157.03	182.85	184.59	134.64
Profit After Tax	153.14	134.54	178.21	180.45	136.56
Operating Profit after Depreciation	256.87	239.25	263.27	269.21	217.89

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	1,580.35	1,475.56	1,474.55	1,588.39	1,478.84
Total Expenses	1,320.86	1,184.14	1,186.36	1,251.25	1,271.38
Profit Before Tax	200.02	213.20	216.16	256.70	133.84
Profit After Tax	165.78	176.19	201.87	233.24	133.84
Operating Profit after Depreciation	275.55	294.57	295.41	340.44	216.41

Alembic Pharmaceuticals Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 898.18

S2 885.27

S3 864.63

Pivot 918.82

R1 931.73

R2 952.37

R3 965.28

Moving Average

20 SMA 1,004.99

50 SMA 1,042.72

100 SMA 1,093.54

200 SMA 1,053.02

Alembic Pharmaceuticals Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

Alembic Pharmaceuticals Ltd

₹11/Share

Announcement Date 15 Jul 2024

Record Date 15 Jul 2024

Div Yield 550%

AGM Date: 11 Nov 2022

AGM 11/11/2022 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith Notice of 12th Annual General Meeting of the Members of the Company scheduled to be held on Friday, the 11th November, 2022 at 3:00 p.m. IST through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'). We request you to kindly take the same on record. (As Per BSE Announcement Dated on 19.09.2022) In accordance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith proceedings of the 12th Annual General Meeting of the Company held on 11th November, 2022. (As Per BSE Announcement dated on 11.11.2022) We would like to inform the exchange that based on the recommendation of Nomination and Remuneration Committee and the Board of Directors, the shareholders of the Company at their 12th Annual General Meeting of the Company held on 11th November, 2022 had approved the re-appointment of Mr. Shaunak Amin (DIN: 00245523) as Managing Director of the Company liable to retire by rotation for a period of 5 years w.e.f. 2nd May, 2023. The proceedings of the aforesaid Annual General Meeting were submitted with the Stock exchanges on 11th November, 2022. In this regard, we hereby declare that Mr. Shaunak Amin is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. (As Per BSE Announcement Dated on 02.05.2023)

AGM Date: 04 Aug 2023

With reference to the captioned subject, we enclose herewith a copy of the advance notice published in 'Economic Times & Indian Express (English Edition) and Financial Express (Gujarati Edition) on 5th June, 2023, in compliance with the procedure prescribed vide various circulars issued from time to time by Ministry of Corporate Affairs and Securities and Exchange Board of India, inter alia informing the members that the 13th Annual General Meeting of the Company will be held on Friday, the 4th August, 2023 through Video Conferencing / Other Audio Visual Means. Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the Annual Report of the Company for the financial year ended 31st March, 2023. We request you to kindly take the same on record. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith Notice of 13th Annual General Meeting of the Members of the Company scheduled to be held on Friday, the 4th August, 2023 at 3:00 p.m. IST through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'). (As Per BSE Announcement Dated on 21.06.2023)

AGM Date: 22 Jul 2024

AGM:22.07.2024 Please find attached herewith the Notice of the 14th AGM of the Company to be held on Monday, 22nd July, 2024. (As Per BSE Announcement dated on 21.06.2024) Please find attached herewith the Voting Results and Scrutinizers'' Report Please find enclosed herewith the Scrutinizers'' Report. Please find attached herewith the Proceedings of the 14th Annual General Meeting held on 22nd July, 2024 (As per BSE Announcement Dated on 22/07/2024)

EGM Date: 14 Jun 2022

COM 14/06/2022 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Notice convening the meeting of Equity Shareholders of the Company scheduled to be held on Tuesday, 14th June, 2022 at 3.00 P.M. IST through Video Conferencing / Other Audio Visual Means for the purpose of considering, and if thought fit, approving, with or without modification(s), the proposed Scheme of Arrangement in the nature of Amalgamation of Aleor Dermaceuticals Limited ('Transferor Company') with Alembic Pharmaceuticals Limited ('Transferee Company') and their respective shareholders ('Scheme'). The said meeting is convened as per the directions of the NCLT vide an Order dated 28th April, 2022 and additional Order dated 9th May, 2022. A copy of the said Notice is uploaded on website of the Company at www.alembicpharmaceuticals.com We request you to kindly take the same on record. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Notice convening the meeting of Secured Creditors of the Company scheduled to be held on Tuesday, 14th June, 2022 at 12.30 P.M. IST through Video Conferencing / Other Audio Visual Means for the purpose of considering, and if thought fit, approving, with or without modification(s), the proposed Scheme of Arrangement in the nature of Amalgamation of Aleor Dermaceuticals Limited ('Transferor Company') with Alembic Pharmaceuticals Limited ('Transferee Company') and their respective shareholders ('Scheme'). The said meeting is convened as per the directions of the NCLT vide an Order dated 28th April, 2022 and additional Order dated 9th May, 2022. A copy of the said Notice is uploaded on website of the Company at www.alembicpharmaceuticals.com We request you to kindly take the same on record. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Notice convening the meeting of Unsecured Creditors of the Company scheduled to be held on Tuesday, 14th June, 2022 at 1:30 P.M. IST through Video Conferencing / Other Audio Visual Means for the purpose of considering, and if thought fit, approving, with or without modification(s), the proposed Scheme of Arrangement in the nature of Amalgamation of Aleor Dermaceuticals Limited ('Transferor Company') with Alembic Pharmaceuticals Limited ('Transferee Company') and their respective shareholders ('Scheme'). The said meeting is convened as per the directions of the NCLT vide an Order dated 28th April, 2022 and additional Order dated 9th May, 2022. A copy of the said Notice is uploaded on website of the Company at www.alembicpharmaceuticals.com We request you to kindly take the same on record. (As per BSE Announcement Dated on 10/5/2022) With reference to the captioned matter and above referred intimations, we would like to inform that the Meetings of the Secured Creditors, Unsecured Creditors and Equity Shareholders of the Company were held on 14th June, 2022 through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'). Please find enclosed herewith: a) Consolidated Scrutinizers' Report on E-voting for the meeting of the Secured Creditors of the Company. b) Consolidated Scrutinizers' Report on E-voting for the meeting of the Unsecured Creditors of the Company. c) Consolidated Scrutinizers' Report on E-voting for the meeting of the Equity Shareholders of the Company. We request you to kindly take the same on record. With reference to the captioned matter and above referred intimation, we would like to inform that the Meeting of the Equity Shareholders of the Company was held on 14th June, 2022 through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'). Please find enclosed herewith: a) Voting Results as required under Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. b) Consolidated Scrutinizers' Report on E-voting (without Annexure) as per the provisions of Section 108 of the Companies Act, 2013 read with Companies (Management and Administration), Rules, 2014. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of Court Convened Meeting, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here (As Per BSE Announcement Dated on 15.06.2022)

Alembic Pharmaceuticals Ltd Peer Comparison

Company	Price	Market Cap (in ₹ Cr)
Alembic Pharmaceuticals Ltd	₹911.55	₹17,917.71
Sun Pharmaceuticals Industries Ltd	₹1,745.25	₹4,18,743.94
Divis Laboratories Ltd	₹5,733.60	₹1,52,209.07
Cipla Ltd	₹1,458.15	₹1,17,762.24
Torrent Pharmaceuticals Ltd	₹3,357.15	₹1,13,616.11
Mankind Pharma Ltd	₹2,488.40	₹1,02,663.15

Alembic Pharmaceuticals Ltd News

Alembic Pharmaceuticals to declare Quarterly Result

On 3 February 2025

23 Jan 2025, 12:03 pm

Alembic Pharma receives USFDA nod for Brexpiprazole tablets

Alembic Pharmaceuticals announced that it has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Brexpiprazole Tablets.

15 Jan 2025, 02:47 pm

Alembic Pharmaceuticals receives USFDA approval for Brexpiprazole Tablets

15 Jan 2025, 12:54 pm

Alembic Pharmaceuticals receives USFDA approval for Divalproex Sodium

20 Dec 2024, 06:30 pm

Alembic Pharma gets USFDA nod for seizure treatment drug

Alembic Pharmaceuticals announced that it has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Divalproex Sodium Delayed-Release Capsules.

20 Dec 2024, 02:20 pm

Alembic Pharmaceuticals Ltd Stock Analysis

Annual revenue for Alembic Pharmaceuticals Ltd increased by 14.61% to ₹5,905.38 crore in FY 2024 from ₹5,152.54 crore in FY 2023.
Annual Net Profit for Alembic Pharmaceuticals Ltd increased by 92.22% to ₹666.48 crore in FY 2024 from ₹346.73 crore in FY 2023.
Promoter Shareholding in Alembic Pharmaceuticals Ltd remains unchanged by 0.00% in the most recent quarter, from 69.61% in September 2024 to 69.61% in December 2024.
Alembic Pharmaceuticals Ltd delivered a 1-year return of 1.10% compared to the Nifty 50, which provided a return of 8.03% as of the last trading session.
Alembic Pharmaceuticals Ltd share price moved up by 0.23% from its previous close of INR ₹911.10. The latest Alembic Pharmaceuticals Ltd share price is INR ₹913.20.
Alembic Pharmaceuticals Ltd share price today has been at a low of 908.15 and a high of 927.95. Over the past 52 weeks, the Alembic Pharmaceuticals Ltd share price has seen a low of 823.40 and a high of 1,303.90.

About Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd stands as a prominent figure in the pharmaceutical industry. It boasts a rich history dating back to its founding in 1907. With over a century of experience, this Gujarat-based company has established itself as a key player in the healthcare sector. It specializes in the manufacture and marketing of branded and generic drugs, as well as active pharmaceutical ingredients (APIs).

Headquartered in Vadodara, Alembic Pharmaceuticals is under the stewardship of the Amin family. Chirayu Amin serves as the Chairman, while Pranav Amin and Shaunak Amin hold positions as Managing Directors. Alembic’s main promoter is Nirayu Limited, which owns a 35.63% stake in the company.

Alembic’s product portfolio is diverse. The company’s products includes antibiotics, anti-infectives, analgesics, and anti-inflammatory drugs, showcasing its expertise in this area. It is not the largest in terms of market share or capitalization. However, Alembic has cultivated a strong reputation in domestic and international markets. This global reach positions them as an influential entity in the pharmaceutical landscape.

The company’s success is driven by a team of managerial promoters who manage operations from the registered office in Vadodara, Gujarat. Their commitment to innovation and quality has allowed Alembic to maintain an edge in its industry. The company’s registrars are also located in Vadodara.

In essence, Alembic Pharmaceuticals Ltd. represents a blend of historical legacy and modern pharmaceutical prowess. Its century-long journey and global presence collectively paint the picture of a company that continues to play a major role in shaping the pharmaceutical sector.

Alembic Pharmaceuticals’ Journey Since 1907

Alembic Pharmaceuticals Ltd. has a rich history that dates back to 1907. Founded in Vadodara, Gujarat, the company began as Alembic Chemical Works Company Limited. Initially, it focused on manufacturing tinctures and alcohol. Over the years, Alembic has evolved into a major player in the pharmaceutical industry. The company is mainly known for its innovation and commitment to quality.

In its early years, Alembic was a pioneer in the Indian pharmaceutical industry. In the 1940s, the company had expanded its product range to include cough syrups and sulfur drugs. This marked the beginning of Alembic’s journey towards becoming a household name in India. The company continued to innovate. In 1961, it inaugurated a dedicated penicillin plant, which was a significant milestone.

The 1970s were a transformative decade for Alembic. In 1971, the company began manufacturing erythromycin, an antibiotic, for the first time in India. This led to the launch of Althrocin, a brand of erythromycin, which became one of the top-selling antibiotics in the country by 1997. Alembic’s commitment to innovation was further demonstrated in the 1990s. This is when it started producing synthetic, organic active pharmaceutical ingredients (APIs).

In the 2000s, Alembic continued to grow and diversify. The company received ISO 14000 certification for its facilities in Vadodara, highlighting its commitment to environmental standards. In 2007, Alembic acquired the non-oncology business of Dabur Pharma Ltd., further expanding its product portfolio. The company also ventured into the production of cephalosporin C, a key antibiotic.

A significant development in Alembic’s history was its demerger from Alembic Ltd. in 2010, leading to the formation of Alembic Pharmaceuticals Ltd. as a separate entity. This move allowed the company to focus more on its core pharmaceutical business. In 2011, Alembic Pharmaceuticals was listed on the BSE and the NSE.

In recent years, Alembic has made significant strides in the global market. The company established a strong presence in the United States, achieving sales milestones. It even received the FDA approvals for its manufacturing facilities. Alembic also created strategic partnerships and joint ventures to enhance its capabilities and market reach. For instance, in 2016, it formed a joint venture with Orbicular to develop dermatology products for the international market.

Alembic’s success can be attributed to its unwavering commitment to quality and sustainability. The company invests heavily in research and development. This is to stay ahead of industry trends and meet the evolving needs of its customers. Alembic’s manufacturing facilities are equipped with the latest technology. They also adhere to stringent quality standards. The company’s focus on sustainability is evident in its efforts to reduce its environmental footprint through various initiatives.

Looking ahead, Alembic aims to continue its growth trajectory by expanding its market share and revenue. The company plans to explore new markets and enhance its product offerings. With its rich legacy and commitment to innovation, Alembic is well-positioned to meet the changing needs of the pharmaceutical industry. It is also ready to contribute to the development of safe and effective medications for patients worldwide.

Overall, Alembic Pharmaceuticals Ltd. has come a long way since its inception in 1907. From its early days of manufacturing tinctures and alcohol to becoming a global player in the pharmaceutical industry, Alembic’s journey is a testament to its resilience and commitment to quality.